Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 June 2025 | Story Dr Nitha Ramnath | Photo Lunga Luthuli
Dr Omololu Aluko
Dr Omololu Aluko, Senior Lecturer in the Department of Biostatistics advances health research and collaboration during prestigious fellowship at Ghent University, Belgium.

Dr Omololu Aluko, Senior Lecturer in the Department of Biostatistics in the Faculty of Health Sciences at the University of the Free State (UFS), recently completed a prestigious short research stay at Ghent University in Belgium. The fellowship, hosted in April 2025, was awarded through the highly competitive Africa Platform of Ghent University Association (GAP) funding scheme, with additional support from the UFS International Office. 

A recognised expert in infectious disease modelling, particularly HIV/AIDS research in low-resource settings, Dr Aluko has devoted his academic career to using biostatistics to address pressing health challenges. His selection for this fellowship marks a significant achievement both for his individual research trajectory and for the broader ambitions of the Faculty of Health Sciences and the UFS.

 

Strategic steps towards international collaboration 

The opportunity for the fellowship was first announced in the UFS Digest Newsletter. Motivated by the potential for international collaboration, Dr Aluko began seeking a host at Ghent University whose interests aligned with his own. After several weeks of correspondence with various departments and researchers, a suitable academic collaborator agreed to host him. 

With a host confirmed, Dr Aluko submitted his application, which underwent a rigorous review and selection process. His proposal was shortlisted and ultimately approved. While Ghent University provided partial funding, supplementary financial support was secured through the UFS International Office. Dr Aluko credits the office’s assistance – especially the guidance of Mr Kagiso Ngake, Senior Officer: Partnerships – for helping him successfully secure the necessary resources. 

 

Advancing research in health data science  

During his time at Ghent University, Dr Aluko focused on the application of machine learning algorithms to address public health challenges – an increasingly important field within the Faculty of Health Sciences. His research demonstrated how advanced data analysis techniques can improve health outcomes and optimise treatment strategies, especially in resource-constrained settings. 

Beyond the immediate research achievements, the fellowship laid a foundation for long-term collaboration between the UFS and Ghent University. Key outcomes include: 

  • Opportunities for joint PhD supervision, allowing UFS students to conduct part of their research at Ghent University 
  • Prospects for publishing collaborative research in leading international A1-rated journals 
  • The identification of a promising young research collaborator, paving the way for future academic partnerships 
  • Plans to explore future staff exchange programmes, as new funding calls are announced 

     

A growing partnership in a new academic field 

Dr Annelies Verdoolaege, Coordinator for the Africa Platform at Ghent University, emphasised the broader vision behind the initiative:

“The purpose of these fellowships is to foster structural academic collaboration between Ghent University and partners in Africa. We offer a dedicated amount of seed funding to support short-term mobility, with the aim of building long-term partnerships – through student exchange, joint PhDs, joint funding proposals, and collaborative research publications. 

The UFS is a long-standing partner of Ghent University, especially in Education, Linguistics, and Agriculture. We are delighted that this fellowship has taken place in the field of Data Analysis and Mathematical Modelling - a scientific domain still to be fully developed between our institutions.” 

 

Enhancing UFS’ global research impact 

Dr Aluko’s successful fellowship reflects the high calibre of researchers at the UFS and illustrates the importance of international academic mobility. By securing this competitive opportunity, Dr Aluko not only advanced his own work but also strengthened the UFS’ global research footprint - opening new collaborative avenues and reinforcing the university's growing reputation in health sciences and data-driven research. 

The UFS expresses its sincere gratitude to the Africa Platform of Ghent University and the UFS International Office for their critical support in enabling this milestone. Partnerships such as this are key to fulfilling the UFS’ mission of producing world-class research and fostering meaningful global engagement. 

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept